Caribou Biosciences, Inc. (CRBU)
NASDAQ: CRBU · Real-Time Price · USD
1.660
+0.050 (3.11%)
At close: Aug 21, 2026, 4:00 PM EDT
1.679
+0.019 (1.15%)
After-hours: Aug 21, 2026, 7:30 PM EDT
Caribou Biosciences Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Caribou Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $11.86. The average 1-year stock price forecast is 614.46% higher than the current stock price, while the lowest is $4.00 (+140.96%) and the highest is $32 (+1,827.71%).
Price Target: $11.86 (+614.46%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Caribou Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains $6 → $5 | Buy | Maintains | $6 → $5 | +201.20% | Aug 14, 2026 |
| Citi | Citi | Buy Reiterates $8 | Buy | Reiterates | $8 | +381.93% | Aug 14, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $10 | Buy | Maintains | $10 | +502.41% | Aug 13, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $11 | Buy | Reiterates | $11 | +562.65% | Jun 16, 2026 |
| Evercore ISI | Evercore ISI | Buy Maintains $11 → $13 | Buy | Maintains | $11 → $13 | +683.13% | Mar 9, 2026 |
Financial Forecast
Revenue This Year
25.45M
from 11.16M
Increased by 128.04%
Revenue Next Year
29.80M
from 25.45M
Increased by 17.09%
EPS This Year
-1.18
EPS Next Year
-1.26
from -1.18
EPS and Forward PE are based on non-GAAP adjusted numbers.